Free cash flow swung to negative $10.5M (-22.2% margin) in 2026Q2 from $11.5M in 2025Q2, and with $776.6K of quarterly dividends and no buybacks, cash conversion appears unstable and warrants further investigation.
LifeMD, Inc. (LFMD) cash flow statement — 15-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Cash from Operations | -10.71M | 8.28M | 17.51M | 8.82M | -22.94M | -33.09M | -12.13M | 251.41K | -905.52K | -817.22K | -407.91K | -295.12K | 33.44K | -259.07K | -229.73K | -17.69K |
| Operating CF Margin % | - | 4.27% | 8.24% | 5.78% | -19.27% | -35.62% | -32.53% | 2.02% | -10.88% | -16.17% | -7.79% | -24.21% | 4.68% | -32.05% | -34.1% | -2.38% |
| Operating CF Growth % | -1120.26% | -52.72% | 98.56% | 138.46% | 30.68% | -172.72% | -4925.47% | 127.76% | -10.81% | -100.34% | -38.22% | -982.57% | 112.91% | -12.78% | -1198.91% | - |
| Net Income | -21.92M | 15.62M | -18.73M | -20.6M | -45.02M | -61.32M | -60.52M | -3.53M | -1.36M | -1.21M | -1.22M | -159.23K | -460.49K | -268.26K | -445.65K | -502.93K |
| Depreciation & Amortization | 8.05M | 7.31M | 9.49M | 6.6M | 3.77M | 868.76K | 397.76K | 335.61K | 195.78K | 91.56K | 33.72K | 43.75K | 56.98K | 56.97K | 56.97K | 56.69K |
| Stock-Based Compensation | 6.58M | 10.5M | 12.23M | 12.49M | 13.73M | 12.07M | 18.66M | 733.22K | 273.57K | 162.74K | 587.99K | 142.3K | 125.5K | 105K | 84K | 400K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 354K | 0 | 914.86K | 66K | 4K | -90.28K | 37.42K | -13.2K | -17.2K | -17.2K | -17.2K | -17.2K |
| Other Non-Cash Items | -17.65M | -17.29M | 1.87M | 5.42M | 5.78M | 6.17M | 19.63M | 578.61K | 237.2K | 918.01K | 33.72K | -127.26K | 80.5K | 48.75K | 122.31K | -17.2K |
| Working Capital Changes | -2.72M | -7.85M | 12.65M | 4.91M | -1.55M | 9.13M | 8.8M | 2.07M | -255.97K | -693.28K | 122.54K | -181.48K | 328.65K | -184.34K | -30.16K | 45.75K |
| Change in Receivables | -11.22M | 1.15M | -2.94M | -2.44M | -2.19M | 17.7K | -550.97K | 1.6K | 29.14K | 95.09K | -361.44K | -139.47K | 62.51K | -27.79K | -13.33K | 43.97K |
| Change in Inventory | -6.31M | 303.24K | 675.67K | 764.33K | -2.18M | -409.82K | -314.2K | 72.56K | -341.36K | -546.89K | -99.22K | -20.04K | 45.19K | -22.82K | -4.58K | 46.2K |
| Change in Payables | 23.29M | 3.24M | 4.92M | 978.06K | 1.25M | -893.96K | 8.93M | 1.89M | 6.34K | -227.23K | 585.45K | -21.97K | 88.96K | -1.73K | -12.24K | -134.41K |
| Cash from Investing | 11.88M | 6.91M | -11.54M | -8.73M | -13.91M | -3.4M | -798.14K | -100K | 141.44K | 63.38K | 219.89K | 127.26K | 0 | 0 | 0 | 0 |
| Capital Expenditures | -4.54M | -1.87M | -1.49M | -203.81K | -366.63K | -247.37K | -398.14K | 0 | -100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 2.4% | 0.96% | 0.7% | 0.13% | 0.31% | 0.27% | 1.07% | - | 1.2% | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | -1.01M | 0 | -400K | -100K | 241.44K | 63.38K | 219.89K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 16.43M | 8.78M | -10.05M | -8.53M | -12.53M | -3.15M | 0 | -100K | 290K | 0 | 0 | 127.26K | 0 | 0 | 0 | 0 |
| Cash from Financing | -3.04M | -13.41M | -4.12M | 29.1M | -528.2K | 68.64M | 21M | 775.12K | 802.79K | 776.03K | 357.49K | 325.35K | -113K | 315.2K | 295.15K | 51.19K |
| Debt Issued (Net) | 0 | -18.72M | -327.6K | 16.67M | 2.74M | -530.82K | 93.19K | 798.28K | 642.44K | 116.06K | 131.4K | 158K | -13K | 40.2K | -50.73K | -142.31K |
| Equity Issued (Net) | 80.52K | 9.19M | 0 | 16.2M | 0 | 69.33M | 20.13M | 350K | 0 | 596.6K | -23.8K | -10.8K | 0 | 175K | 345.88K | 193.5K |
| Dividends Paid | -3.11M | -3.11M | -3.11M | -3.11M | -3.11M | -871.48K | -1.29M | 0 | 0 | 0 | 0 | -10.8K | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -76.65K | -87.05K | -10.8K | 0 | 0 | 0 | 0 |
| Other Financing | -12K | -773.66K | -684.83K | -667.63K | -159.2K | 707.36K | 2.07M | -373.15K | 160.35K | 63.38K | 249.89K | 188.95K | -100K | 100K | 0 | 0 |
| Net Change in Cash | -1.86M | 1.78M | 1.86M | 29.19M | -37.37M | 32.15M | 8.07M | 926.53K | 38.71K | -41.18K | -50.42K | 157.49K | -79.56K | 56.13K | 65.43K | 33.5K |
| Free Cash Flow | -16.05M | -1.24M | 5.98M | 86.95K | -35.83M | -36.49M | -12.53M | 251.41K | -1.01M | -817.22K | -407.91K | -295.12K | 33.44K | -259.07K | -229.73K | -17.69K |
| FCF Margin % | -8.5% | -0.64% | 2.81% | 0.06% | -30.1% | -39.29% | -33.6% | 2.02% | -12.08% | -16.17% | -7.79% | -24.21% | 4.68% | -32.05% | -34.1% | -2.38% |
| FCF Growth % | -194.56% | -120.72% | 6774.08% | 100.24% | 1.81% | -191.21% | -5083.83% | 125% | -23.04% | -100.34% | -38.22% | -982.57% | 112.91% | -12.78% | -1198.91% | - |
| FCF per Share | -0.33 | -0.03 | 0.15 | 0.00 | -1.16 | -1.35 | -0.88 | 0.03 | -0.11 | -0.09 | -0.06 | -0.05 | 0.01 | -0.04 | -0.04 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.73x | -1.17x | -0.93x | -0.43x | 0.50x | 0.54x | 0.21x | -0.08x | 0.73x | 0.68x | 0.37x | 4.76x | -0.07x | 0.97x | 0.52x | 0.04x |
| Interest Paid | 0 | 0 | 0 | 0 | 189K | 435.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LFMD stock.
LifeMD, Inc. (LFMD) generated $8.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
LifeMD, Inc. (LFMD) reported negative free cash flow of $1.2M in 2025, indicating capital requirements exceeded cash from operations.
LifeMD, Inc. (LFMD) spent $1.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, LifeMD, Inc. (LFMD) returned $3.1M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Operating cash flow reversal persists
Metrics are mathematically derived from official filings.
Net Losses Mask Erratic Operating Cash
Based on LifeMD's reported quarterly figures, operating cash flow swung from $8.6M in 2025Q2 to negative $6.9M in 2026Q2, producing an OCF-to-net-income ratio that lacks a stable meaning across the ten quarters examined.
The ratio is distorted by the sign changes in net income, so 2024Q4's ratio of -14.76 and 2025Q1's ratio of 2.22 reflect noise rather than earnings quality. The more informative observation is that operating cash flow turned negative in the latest quarter while net losses also widened, suggesting the business is not currently converting revenue into cash. Investors should monitor whether the 2026Q2 outflow reflects working capital timing or a sustained operating deficit.
Free Cash Flow Turns Sharply Negative
According to reported cash flow statements, LifeMD's free cash flow fell to negative $10.5M in 2026Q2, a -22.2% margin, after a peak of $11.5M in 2025Q2 when the margin reached 18.5%.
Free cash flow has oscillated rather than trended, with the margin ranging from roughly -22% to +18% over the period. The latest quarter's deterioration coincides with contracting revenue, which suggests the swings are driven by operating volatility rather than a stable cash generation base. The pattern warrants further investigation into whether the 2025Q2 peak was representative or an outlier.
Working Capital Swings Drive Cash Volatility
Based on LifeMD's reported figures, working capital changes ranged from a $6.9M inflow in 2024Q3 to a $5.7M inflow in 2026Q1 and a $2.9M outflow in 2026Q2, indicating that timing effects are a material driver of quarterly cash flow.
The magnitude of working capital movements is comparable to the operating cash flow itself in several quarters, implying that reported operating cash generation is highly sensitive to receivable, inventory, and payable timing. Quarters with large inflows may reverse, so the underlying cash earnings power is likely lower than any single quarter suggests. Investors should monitor whether working capital reversals continue to offset or mask operating performance.
Dividend Outflows Exceed Cash Generation
As reported in financial statements, LifeMD paid $776.6K in dividends in every quarter examined and recorded no buybacks or acquisitions, so distributions were funded from cash flows that were negative in several periods.
The fixed quarterly dividend is small relative to the company's cash flow volatility, yet it is paid consistently even in quarters with negative free cash flow of -$10.5M. This suggests distributions are not currently covered by internally generated free cash flow over the period. The absence of buybacks and acquisitions indicates capital is being preserved rather than actively deployed, which may be appropriate given the losses but limits evidence of disciplined capital allocation.
Stock Compensation Inflates Cash Picture
Based on LifeMD's reported figures, stock-based compensation of $2.1M to $4.2M per quarter represents a non-cash add-back, and it may flatter operating cash flow relative to the economic cost borne by shareholders.
Because SBC is added back in operating cash flow, the reported cash figures exclude a recurring cost of compensating staff, which can make a loss-making business appear closer to cash breakeven than it is. The 2025Q2 operating cash flow peak occurred alongside $2.1M of SBC, so the peak is not explained by non-cash charges alone. Investors should monitor whether dilution from equity compensation offsets any apparent improvement in cash generation.